Published in J Viral Hepat on April 01, 2008
KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol (2012) 2.10
Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling. Hepatology (2014) 1.74
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis (2015) 1.59
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol (2010) 1.56
KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol (2016) 1.07
Establishment of a novel quantitative hepatitis D virus (HDV) RNA assay using the Cobas TaqMan platform to study HDV RNA kinetics. J Clin Microbiol (2010) 1.00
Hepatitis delta: epidemiology, diagnosis and management 36 years after discovery. Curr Gastroenterol Rep (2014) 0.86
Treatment of chronic delta hepatitis: a nine-year retrospective analysis. Hepat Mon (2011) 0.84
Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol (2012) 0.83
Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis. J Res Med Sci (2012) 0.82
Molecular and clinical aspects of hepatitis D virus infections. World J Virol (2012) 0.81
Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med (2015) 0.76
Direct acting antivirals for the treatment of chronic viral hepatitis. Scientifica (Cairo) (2012) 0.75
Interferon alpha-2b therapy in chronic hepatitis delta. Hepat Mon (2014) 0.75
Therapeutic Strategies and New Intervention Points in Chronic Hepatitis Delta Virus Infection. Int J Mol Sci (2015) 0.75
Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retroviruses (2013) 0.75
Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin. Clin Pract (2012) 0.75
Hepatitis delta virus: A fascinating and neglected pathogen. World J Virol (2015) 0.75
Recent advances in managing hepatitis D. F1000Res (2017) 0.75
DNA polymerase associated with human hepatitis B antigen. J Virol (1973) 10.71
Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature (1986) 7.38
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol (2000) 5.76
delta Agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A (1980) 5.12
Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis (1980) 4.28
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A (1991) 3.82
Expression of the hepatitis B virus surface antigen gene in cell culture by using a simian virus 40 vector. Proc Natl Acad Sci U S A (1981) 3.38
Australia antigen: large-scale purification from human serum and biochemical studies of its proteins. J Virol (1971) 3.28
Antigens of hepatitis delta virus in the liver and serum of humans and animals. J Infect Dis (1986) 3.08
Live recombinant vaccinia virus protects chimpanzees against hepatitis B. Nature (1984) 3.03
A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta. J Virol (1988) 2.99
An assay for the detection of the DNA genome of hepatitis B virus in serum. J Med Virol (1982) 2.94
Transmission of the hepatitis B virus-associated delta agent to the eastern woodchuck. Proc Natl Acad Sci U S A (1984) 2.87
The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol (1993) 2.84
Delta hepatitis agent: structural and antigenic properties of the delta-associated particle. Infect Immun (1984) 2.81
Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med (1976) 2.67
Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis (1974) 2.66
Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrob Agents Chemother (1997) 2.64
Immunochemical identification of viral and nonviral proteins of the respiratory syncytial virus virion. Infect Immun (1982) 2.61
The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol (1980) 2.57
Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. J Virol (1995) 2.54
Biophysical properties of Australia antigen. J Virol (1969) 2.45
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology (2001) 2.30
Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet (1979) 2.29
Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med (1978) 2.29
A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A (1993) 2.25
Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet (1980) 2.17
Demonstration of subpopulations of Dane particles. J Virol (1976) 2.14
Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res (1992) 2.08
Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract. J Infect Dis (1999) 2.07
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest (2001) 2.05
Radioimmunoassay for the detection of the core of the Dane particle and antibody to it. Intervirology (1974) 2.02
Chemically synthesized peptides of hepatitis B surface antigen duplicate the d/y specificities and induce subtype-specific antibodies in chimpanzees. Proc Natl Acad Sci U S A (1983) 2.00
Core antigen and antibody in woodchucks after infection with woodchuck hepatitis virus. J Virol (1984) 1.97
Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc Natl Acad Sci U S A (1987) 1.93
Viral hepatitis, type B, DNA polymerase activity and antibody to hepatitis B core antigen. N Engl J Med (1974) 1.92
Potent and selective in vitro activity of 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) against human immunodeficiency virus. Biochem Pharmacol (1987) 1.89
Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci U S A (1992) 1.87
Monoclonal antibodies to respiratory syncytial virus: detection of virus neutralization and other antigen-antibody systems using infected human and murine cells. J Virol Methods (1981) 1.78
Biophysical characterization of the adr subtype of hepatitis B antigen and preparation of anti-r sera in rabbits. J Immunol (1975) 1.75
Density in cesium chloride of the 27 nm "8FIIa" particle associated with acute infectious nonbacterial gastroenteritis: determination by ultra-centrifugation and immune electron microscopy. Proc Soc Exp Biol Med (1973) 1.73
Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob Agents Chemother (2001) 1.72
Proteins of hepatitis B surface antigen. J Virol (1977) 1.71
Woodchuck hepatitis and hepatocellular carcinoma: correlation of histologic with virologic observations. Hepatology (1981) 1.67
The stabilization and purification of respiratory syncytial virus using MgSO4. Virology (1980) 1.63
Non-specificity of anti-HCV test for seroepidemiological analysis. Lancet (1990) 1.62
Preparation and characterization of complement-fixing hepatitis-associated antigen and antiserum. J Infect Dis (1970) 1.62
Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res (1999) 1.62
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother (2000) 1.60
The development of Balb/c cells persistently infected with respiratory syncytial virus: presence of ribonucleoprotein on the cell surface. Proc Soc Exp Biol Med (1981) 1.56
Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2'-deoxycytidine kinase. Biochem Pharmacol (1993) 1.56
The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol (1992) 1.52
Immunochemistry of hepatitis B surface antigen (HBsAg): preparation and characterization of antibodies to the constituent polypeptides. J Immunol (1975) 1.52
Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2'-deoxynucleoside triphosphates. Antimicrob Agents Chemother (2000) 1.49
Effect of combinations of acyclovir with vidarabine or its 5'-monophosphate on herpes simplex viruses in cell culture and in mice. Antimicrob Agents Chemother (1982) 1.48
The delta agent: HBsAg particles with delta antigen and RNA in the serum of an HBV carrier. Hepatology (1981) 1.47
Enzyme-linked immunosorbent assay for detection of antibody to the hepatitis B surface antigen-associated delta antigen. J Clin Microbiol (1981) 1.47
Cloned fragment of the hepatitis delta virus RNA genome: sequence and diagnostic application. Science (1986) 1.46
Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology (1987) 1.44
Anti-human immunodeficiency virus activities of the beta-L enantiomer of 2',3'-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob Agents Chemother (1994) 1.43
Hepatitis B subunit vaccine: a preliminary report of safety and efficacy tests in chimpanzees. Am J Med Sci (1977) 1.43
Production of monoclonal antibodies against hepatitis B surface antigen (HBsAg) by somatic cell hybrids. J Virol Methods (1980) 1.43
Hepadnavirus infection of peripheral blood lymphocytes in vivo: woodchuck and chimpanzee models of viral hepatitis. J Virol (1986) 1.43
Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest (1995) 1.42
Combined antiviral effect of interferon and acyclovir on herpes simplex virus types 1 and 2. Antimicrob Agents Chemother (1981) 1.41
Complete nucleotide sequence of a molecular clone of woodchuck hepatitis virus that is infectious in the natural host. Proc Natl Acad Sci U S A (1989) 1.41
Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates. Antimicrob Agents Chemother (1995) 1.39
Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology (1989) 1.39
Cellular replication of human immunodeficiency virus type 1 occurs in vaginal secretions. J Infect Dis (2001) 1.38
Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A (1994) 1.38
Uridine reverses the toxicity of 3'-azido-3'-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity. Antimicrob Agents Chemother (1988) 1.36
Lymphoid cells in the spleens of woodchuck hepatitis virus-infected woodchucks are a site of active viral replication. J Virol (1987) 1.36
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. Proc Natl Acad Sci U S A (1992) 1.35
Biochemical characterization of Australia antigen. Evidence for defective particles of hepatitis B virus. Am J Pathol (1975) 1.35
Properties of delta-associated ribonucleic acid. Prog Clin Biol Res (1983) 1.34
Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV). J Med Chem (1988) 1.33
A human monoclonal antibody that recognizes viral polypeptides and in vitro translation products of the genome of the hepatitis D virus. J Infect Dis (1987) 1.32
Use of zonal ultracentrifuge systems for biophysical studies of rhinoviruses. J Virol (1968) 1.32
Classification of hybridomas to respiratory syncytial virus glycoproteins. Proc Soc Exp Biol Med (1982) 1.32
1,3-dioxolanylpurine nucleosides (2R,4R) and (2R,4S) with selective anti-HIV-1 activity in human lymphocytes. J Med Chem (1993) 1.31
An ultraviolet-sensitive RNA structural element in a viroid-like domain of the hepatitis delta virus. Science (1989) 1.31
Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol (2000) 1.30
The demonstration of subtype (D or Y)-specific determinants on the surface of the presumed hepatitis B virus. J Immunol (1977) 1.29
Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. Antimicrob Agents Chemother (1986) 1.28
Hepatitis B vaccines. On the threshold. Am J Clin Pathol (1978) 1.28
DNA vaccine for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with other vaccines. Proc Natl Acad Sci U S A (1996) 1.28
Buoyant density of the hepatitis A virus-like particle in cesium chloride. J Virol (1974) 1.27
Characterization of antibodies to the structural polypeptides of HGSAg: evidence for subtype-specific determinants. J Immunol (1976) 1.27
Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology (2000) 1.27
Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology (1998) 1.26
Multiple drug effect analysis with confidence interval. Antiviral Res (1994) 1.26
Natural and experimental infection of woodchucks with woodchuck hepatitis virus, as measured by new, specific assays for woodchuck surface antigen and antibody. J Clin Microbiol (1982) 1.26
Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis (1996) 1.26
Hepatitis delta virus (HDV) and woodchuck hepatitis virus (WHV) nucleic acids in tissues of HDV-infected chronic WHV carrier woodchucks. J Virol (1989) 1.26
3'-Azido-2',3'-dideoxyuridine (AzddU): comparative pharmacokinetics with 3'-azido-3'-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses (1990) 1.24
Purification of influenza virus in the K-II zonal centrifuge. Nature (1969) 1.24
Comparison of the Sit-to-Stand Test with 6 min walk test in patients with chronic obstructive pulmonary disease. Respir Med (2006) 1.23
All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat (2013) 1.23